=

Upday the Pasesyork Reduction Act of 1028, as some as a required	PTC. 88-88 (27-20 Approved for use through 7/61/2006. DAIB 3651-005 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMER 3
Under the Paciety ork Reduction Act of 1998, no persons are recuired to reso REQUEST FOR ACCESS TO AN ABANDONED	sna id a sociedian of information unless it discleys a velic OMB conuct numbe. D APPLICATION UNDER 37 CFR 1.14
Bring completed form to: File Information Unit Crystal Plaza Three, Room 150 2021 South Clark Place Arlington, VA Telephone: (703) 308-2733 Telephone: (703) 308-2733	Application Number Filed O71746,020 8-15-91 Paper No. #14
I hereby request access under 37 OFR 1.14(a)(1)(iv) to the app application, which is identified in, or to which a benefit is pial attachment): _	med, in the following document (as shown in the
United States Patent Application Publication No.	
United States Patent Number 5, 674, 882, colu	mn, iins,cr
WIPO Pub. No, page,	line
Related Information about Access to Pending. Direct access to pending applications is not available to it purchased from the Office of Public Records upon payment of For published applications that are still pending, a member of the file contents; the pending application as originally filed; or any document in the file of the pending application. For unpublished applications that are still pending: (1) If the benefit of the pending application is claimed unde application that has: (a) issued as a U.S. patent, or (b) patent application publication, or an international patent Article 21(2), a member of the public may obtain a copy the file contents; the pending application as originally filed; or any document in the file of the pending application. (2) If the application is incorporated by reference or otherwing registration, a U.S. patent application publication, or an accordance with PCT Article 21(2), a member of the public the pending application as originally filed.	ne public but copies may be available and may be if the appropriate fee (37 CFR 1.19(b)), as follows: of the public may obtain a copy of: r 35 U.S.C. 119(e), 120, 121, or 365 in another published as a statutory invention registration, a U.S. application publication in accordance with PCT y of: n. ise identified in a U.S. patent, a statutory invention international patent application publication in
Zahu Hall	10-01-03
Rand Haile Typed or printed name	FOR PTO USE ONLY
Registration Number, if applicable 103 - 406 - 1150	Unit: OCT 0.1 2003
Telephone Number	File I
s collection of information is required by 37 CFR 1.14. The information is required to rocess) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.1	File Inf: postain or relain a benefit by the public which is to file (and by the USPTO

gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1001, 2021 South Clark Place, Arlington, VA.



US005674882A

United States Patent [19]

Kempf et al.

Patent Number:

5,674,882

Date of Patent:

Oct. 7, 1997

[54] RETROVIRAL PROTEASE INHIBITING COMPOUNDS

[75] Inventors: Dale J. Kempf, Libertyville; Daniel W. Norbeck, Crystal Lake; Hing Leung Sham; Chen Zhao, both of Gurnec, all

[73] Assignce: Abbott Laboratories, Abbott Park, Ill.

[21] Appl. No.: 413,136

[22] Filed: Mar. 29, 1995

Related U.S. Application Data

[60] Division of Ser. No. 158,587, Dec. 2, 1993, abandoned, which is a continuation-in-part of Ser. No. 998,114, Dec. 29, 1992, abandoned, which is a continuation-in-part of Ser. No. 777,626, Oct. 23, 1991, which is a continuation-in-part of Ser. No. 746,020, Aug. 15, 1991, abandoned, which is a confinuation-in-part of Ser. No. 616,170, Nov. 20, 1990, abandoned, which is a continuation-in-part of Ser. No. 518,730, May 9, 1990, Pat. No. 5,142,056, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 355,945, May 23, 1989, abandoned.

[52] U.S. Cl. 514/365; 514/374

[58] Field of Search 514/365, 374

References Cited [56]

U.S. PATENT DOCUMENTS

4,172,094	10/1979	Dybas et al 544/396
4,618,619	10/1986	Regel et al 514/383
4,644,055	2/1987	Kettner et al 530/330
4,652,552	3/1987	Kettner et al 514/18
5,142,056	8/1992	Kempf et al 546/265
5,354,866	10/1994	Kempf et al 546/265

Primary Examiner—Russell Travers

Attorney, Agent, or Firm-Steven R. Crowley

ABSTRACT

A retroviral protease inhibiting compound of the formula:

is disclosed.

3 Claims, No Drawings